Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Disease activity significantly decreased from baseline (mean DAS28-CRP 4.3, SD 0.9) to M12 (mean DAS28-CRP 2.3, SD 1.1), p for linear trend < 0.0001 (Figure S1 supplementary materials).Characteristics of the study population.Characteristicsn = 33Sex, female (%)28 (85%)Age, years (SD)59.0 (13.1)Menopause, n (% of 28 women)23 (82%)Weight, kg (SD)76.3 (14.7)Height, cm (SD)165 (7)ACPA positive, n (%)33 (100%)RF positive, n (%)26 (78.8%)Disease duration, years (SD)1.2 (0.4)Baseline swollen joints, n (IQR)5 (4)Baseline tender joints, n (IQR)5 (5)Baseline PGA (IQR)6 (2)Baseline PhGA (IQR)7 (2)Baseline CRP serum levels, mg/L (IQR)3 (6.5)Baseline DAS28-CRP (SD)4.3 (0.9)Month 12 DAS28-CRP (SD)Baseline mSvdH score (IQR)25 (46.25)Treatment with cDMARD, n (%) Methotrexate26 (79%) Leflunomide6 (18%) Sulfasalazine3 (9%)Vitamin D supplements taking, n (%)26 (79%)GC taking, n (%)20 (61%)GC daily dose at enrollment, mg (IQR)5 (5)GC cumulative dose prior to enrollment, mg (IQR)1291 (2196)GC cumulative dose during study period, mg (IQR)300 (784.5)GC daily dose at month 12, mg (IQR)0 (3.25)ACPA titer, IU (IQR)853 (1584)RF titer, IU (IQR)60 (130)Smoking habit, n (%) No18 (55%) Yes8 (24%) Former7 (21%)Charlson Comorbidity Index (IQR)2 (2.25)SD standard deviation; ACPA anti-citrullinated proteins antibodies; RF rheumatoid factor; IQR interquartile range; PGA patient global assessment; PhGA physician global assessment; CRP c-reactive protein; DAS28 disease activity score 28-joints; csDMARD conventional synthetic disease modifying anti-rheumatic drugs; GC glucocorticoids.

Source: Patients characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a prospective observational study on patients with active seropositive RA failure to biological disease modifying anti-rheumatic drugs initiating treatment with abatacept.

Source: Abstract.

Throughout a 12-month period, the patients were regularly monitored and underwent control visits and study procedures at specific time points: baseline (B), month 1 (M1), month 2 (M2), month 3 (M3), month 6 (M6), month 9 (M9), and month 12 (M12).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Changes in bone turnover markers and bone modulators during abatacept treatment

Observational study · Scientific Reports · 2023

Original publication title

Changes in bone turnover markers and bone modulators during abatacept treatment

Giovanni Adami; Giovanni Orsolini; Maurizio Rossini; Elisa Pedrollo; Anna Fratucello; Angelo Fassio; Ombretta Viapiana; Stefano Milleri; Elena Fracassi; Riccardo Bixio; Davide Gatti

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Rheumatoid arthritis (RA) causes bone loss, only partly related to inflammation. The impact of RA treatments on bone metabolism and their ability to mitigate bone loss remains uncertain. The primary goal of our study was to examine the influence of abatacept on serum levels of markers and regulators involved in bone turnover. Secondary objectives included evaluating changes in bone mineral density (BMD), bone health parameters, erosions, and exploring potential correlations among these parameters. We conducted a prospective observational study on patients with active seropositive RA failure to biological disease modifying anti-rheumatic drugs initiating treatment with abatacept.

We measured at baseline and after 1, 2, 3, 6, 9 and 12 months: serum bone turnover markers (CTX, P1nP, B-ALP), bone modulators (Dkk-1, sclerostin, vitamin D, PTH, OPG and RANKL), BMD and radiographic parameters (modified Sharp van der Heijde score [mSvdH], bone health index [BHI] and metacarpal index [MCI]). Disease activity and glucocorticoid intake was monitored. 33 patients were enrolled in the study. We found a significant increase in markers of bone formation (B-ALP and P1nP) from baseline to M6 and M12.

PTH increased significantly at M6 but not at M12. All other bone markers and modulators did not change. We found a significant decrease in BHI and MCI from baseline to M12 (median difference − 0.17 95% CI − 0.42 to − 0.10, p 0.001 and − 0.09 95% CI − 0.23 to − 0.07, respectively). BMD at femoral neck transitorily decreased at M6 (mean difference − 0.019 g/cm2 95% CI − 0.036 to − 0.001 p 0.04). BMD at total hip, lumbar spine and mSvdH score did not change significantly.

P1nP delta at M12 correlated with delta mSvdH. Treatment with abatacept was associated with a significant increase in bone formation markers. The secondary and transient increase in PTH serum levels may be responsible of the transitory bone loss.

Authors’ abstract

Rheumatoid arthritis (RA) causes bone loss, only partly related to inflammation. The impact of RA treatments on bone metabolism and their ability to mitigate bone loss remains uncertain. The primary goal of our study was to examine the influence of abatacept on serum levels of markers and regulators involved in bone turnover. Secondary objectives included evaluating changes in bone mineral density (BMD), bone health parameters, erosions, and exploring potential correlations among these parameters. We conducted a prospective observational study on patients with active seropositive RA failure to biological disease modifying anti-rheumatic drugs initiating treatment with abatacept.

We measured at baseline and after 1, 2, 3, 6, 9 and 12 months: serum bone turnover markers (CTX, P1nP, B-ALP), bone modulators (Dkk-1, sclerostin, vitamin D, PTH, OPG and RANKL), BMD and radiographic parameters (modified Sharp van der Heijde score [mSvdH], bone health index [BHI] and metacarpal index [MCI]). Disease activity and glucocorticoid intake was monitored. 33 patients were enrolled in the study. We found a significant increase in markers of bone formation (B-ALP and P1nP) from baseline to M6 and M12.

PTH increased significantly at M6 but not at M12. All other bone markers and modulators did not change. We found a significant decrease in BHI and MCI from baseline to M12 (median difference − 0.17 95% CI − 0.42 to − 0.10, p 0.001 and − 0.09 95% CI − 0.23 to − 0.07, respectively). BMD at femoral neck transitorily decreased at M6 (mean difference − 0.019 g/cm2 95% CI − 0.036 to − 0.001 p 0.04). BMD at total hip, lumbar spine and mSvdH score did not change significantly.

P1nP delta at M12 correlated with delta mSvdH. Treatment with abatacept was associated with a significant increase in bone formation markers. The secondary and transient increase in PTH serum levels may be responsible of the transitory bone loss.

Publication and source details

Original title: Changes in bone turnover markers and bone modulators during abatacept treatment

Giovanni Adami; Giovanni Orsolini; Maurizio Rossini; Elisa Pedrollo; Anna Fratucello; Angelo Fassio; Ombretta Viapiana; Stefano Milleri; Elena Fracassi; Riccardo Bixio; Davide Gatti

Scientific Reports · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Research was supported by an unrestricted grant by Bristol Myers Squibb.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:00:42.356509+00:00

DOI: 10.1038/s41598-023-44374-2 · PMC10567677